Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Cab + atezo: a new treatment for naïve advanced ccRCC

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses results from a Phase Ib trial, COSMIC-021 (NCT03170960), investigating the use of cabozantinib in combination with atezolizumab as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC). This study showed that cabozantinib plus atezolizumab demonstrated encouraging anti-tumor activity in patients with advanced ccRCC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

The content of VJOncology is intended for healthcare professionals